Skip to content

Opko Health OPK Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Immunome logo
ImmunomeIMNM
-$79K

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's gain/loss on asset sales?
Opko Health (OPK) reported gain/loss on asset sales of $34K in Q1 2026.
How has Opko Health's gain/loss on asset sales changed year-over-year?
Opko Health's gain/loss on asset sales decreased by 99.1% year-over-year, from $3.79M to $34K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.